Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Dec 28,2023
Medicilon was awarded the "Industry Outstanding Member Unit Management Award" by the China Laboratory Primate Breeding and Development Association
Recently, the China Laboratory Primate Breeding and Development Association Industry Academic Exchange Conference and 30th Anniversary Celebration were held as scheduled at the Dragon Lake Princess Hotel in Huadu, Guangzhou. As a member, Shanghai Medicilon Inc. was invited to attend the conference and was awarded the "Industry Outstanding Member Unit Management Award".
More
Medicilon was awarded the "Industry Outstanding Member Unit Management Award" by the China Laboratory Primate Breeding and Development Association
Dec 22,2023
Pharmalego intermediates e-commerce platform launched; We have what scientific researchers are struggling to find
From a one-stop biopharmaceutical preclinical R&D service platform, to Medicilon Academician Innovative Drug Maturation Center and New Drug Ecological Assistance Platform, to building a pharmaceutical network (PharmalegoTM), Medicilon is willing to help you overcome the obstacles on the journey of new drug research and development.
More
Pharmalego intermediates e-commerce platform launched; We have what scientific researchers are struggling to find
Dec 12,2023
Build a new drug empowerment ecosystem, Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference was successfully completed
On November 30, the "Focus on the development of innovative drugs and promote the upgrading of the industrial chain - Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference" hosted by Shanghai Medicilon Inc. (Medicilon) was grandly held.
More
Build a new drug empowerment ecosystem, Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference was successfully completed
Nov 28,2023
Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison Patent Award
Dr. Liu Jian, President of the Drug Discovery Division at Medicilon, has been awarded the Thomas Alva Edison Patent Award for 2023 from the New Jersey Research and Development Committee.
More
Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison Patent Award
Oct 25,2023
Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189
On October 10, 2023, Simcere Pharmaceutical Group Ltd. (2096.HK) announced that they entered into a collaboration agreement with Jiaxing AnDiCon Biotech Co., Ltd. (AnDiCon) on the anti-influenza innovative drug ADC189.
More
Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189
Oct 25,2023
Successful registration of ABSL-2 laboratory! Medicilon becomes a one-stop biopharmaceutical preclinical CRO with both ABSL-2 and BSL-2 laboratories
On October 12, 2023, the ABSL-2 laboratory of Shanghai Medicilon Inc. (Medicilon) obtained the "Registration Certificate for Animal Pathogenic Microorganisms Laboratory in Pudong New Area, Shanghai" issued by the Shanghai Pudong New Area Agriculture and Rural Affairs Committee.
More
Successful registration of ABSL-2 laboratory!  Medicilon becomes a one-stop biopharmaceutical preclinical CRO with both ABSL-2 and BSL-2 laboratories
Oct 17,2023
Medicilon was selected as "2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise"
Shanghai Medicilon Inc (Medicilon) has been selected as a " 2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise" based on its hard-core advantages in biopharmaceutical technology innovation over the years.
More
Medicilon was selected as "2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise"
Sep 20,2023
Medicilon's Interview: See how Dr. Chen Chen from ABM Therapeutics crosses the blood-brain barrier
Shanghai Medicilon Inc. (Medicilon) has the honor to invite Dr. Chen Chen, Founder and Chairman of ABM Therapeutics, to discuss the unique technical advantages and R&D strategies of ABM Therapeutics in developing brain-targeted drugs, as well as the inner journey and profound insights.
More
Medicilon's Interview: See how Dr. Chen Chen from ABM Therapeutics crosses the blood-brain barrier
Aug 14,2023
Medicilon was selected into the SSE Science and Technology Innovation Board 100 Index, R&D intensity and revenue growth have been recognized
On August 7, 2023, the Shanghai Stock Exchange officially launched the SSE Science and Technology Innovation Board 100 Index. Shanghai Medicilon Inc. was selected as one of the SSE Science and Technology Innovation Board 100 Index.
More
Medicilon was selected into the SSE Science and Technology Innovation Board 100 Index, R&D intensity and revenue growth have been recognized
Jul 31,2023
Medicilon interview with Dr. Xin Dong - In the field of immunotherapy, where the fierce competition is in full swing, where does Neologics Bioscience come from?
Medicilon interviewed Dr. Xin Dong to get a glimpse of his profound insights in the field of immunotherapy, and "learn from the experience" to grow in the era of new drugs.
More
Medicilon interview with Dr. Xin Dong - In the field of immunotherapy, where the fierce competition is in full swing, where does Neologics Bioscience come from?
Jul 28,2023
Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together
On July 25, 2023, Fosun Health Capital established by Fosun Pharma(stock code:600196.SH), reached a strategic partnership with Medicilon(stock code: 688202.SH).
More
Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together
Jul 27,2023
The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award
Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award the Medicilon DMPK team the "Best Partner Award" to express their gratitude and recognition.
More
The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award